van der Meulen, M., Zamanipoor Najafabadi, A. H., Lobatto, D. J., Andela, C. D., Vliet Vlieland, T. P. M., Pereira, A. M., . . . Biermasz, N. R. (2020). SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements. Endocrine.
シカゴスタイル引用形van der Meulen, Merel, Amir H. Zamanipoor Najafabadi, Daniel J. Lobatto, Cornelie D. Andela, Thea P. M. Vliet Vlieland, Alberto M. Pereira, Wouter R. van Furth, , Nienke R. Biermasz. "SF-12 or SF-36 in Pituitary Disease? Toward Concise and Comprehensive Patient-reported Outcomes Measurements." Endocrine 2020.
MLA引用形式van der Meulen, Merel, et al. "SF-12 or SF-36 in Pituitary Disease? Toward Concise and Comprehensive Patient-reported Outcomes Measurements." Endocrine 2020.